Cargando…

Cognitive biomarker prioritization in Alzheimer’s Disease using brain morphometric data

BACKGROUND: Cognitive assessments represent the most common clinical routine for the diagnosis of Alzheimer’s Disease (AD). Given a large number of cognitive assessment tools and time-limited office visits, it is important to determine a proper set of cognitive tests for different subjects. Most cur...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Bo, Yao, Xiaohui, Risacher, Shannon L., Saykin, Andrew J., Shen, Li, Ning, Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709267/
https://www.ncbi.nlm.nih.gov/pubmed/33267852
http://dx.doi.org/10.1186/s12911-020-01339-z
_version_ 1783617712845488128
author Peng, Bo
Yao, Xiaohui
Risacher, Shannon L.
Saykin, Andrew J.
Shen, Li
Ning, Xia
author_facet Peng, Bo
Yao, Xiaohui
Risacher, Shannon L.
Saykin, Andrew J.
Shen, Li
Ning, Xia
author_sort Peng, Bo
collection PubMed
description BACKGROUND: Cognitive assessments represent the most common clinical routine for the diagnosis of Alzheimer’s Disease (AD). Given a large number of cognitive assessment tools and time-limited office visits, it is important to determine a proper set of cognitive tests for different subjects. Most current studies create guidelines of cognitive test selection for a targeted population, but they are not customized for each individual subject. In this manuscript, we develop a machine learning paradigm enabling personalized cognitive assessments prioritization. METHOD: We adapt a newly developed learning-to-rank approach [Formula: see text] to implement our paradigm. This method learns the latent scoring function that pushes the most effective cognitive assessments onto the top of the prioritization list. We also extend [Formula: see text] to better separate the most effective cognitive assessments and the less effective ones. RESULTS: Our empirical study on the ADNI data shows that the proposed paradigm outperforms the state-of-the-art baselines on identifying and prioritizing individual-specific cognitive biomarkers. We conduct experiments in cross validation and level-out validation settings. In the two settings, our paradigm significantly outperforms the best baselines with improvement as much as 22.1% and 19.7%, respectively, on prioritizing cognitive features. CONCLUSIONS: The proposed paradigm achieves superior performance on prioritizing cognitive biomarkers. The cognitive biomarkers prioritized on top have great potentials to facilitate personalized diagnosis, disease subtyping, and ultimately precision medicine in AD.
format Online
Article
Text
id pubmed-7709267
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77092672020-12-02 Cognitive biomarker prioritization in Alzheimer’s Disease using brain morphometric data Peng, Bo Yao, Xiaohui Risacher, Shannon L. Saykin, Andrew J. Shen, Li Ning, Xia BMC Med Inform Decis Mak Research Article BACKGROUND: Cognitive assessments represent the most common clinical routine for the diagnosis of Alzheimer’s Disease (AD). Given a large number of cognitive assessment tools and time-limited office visits, it is important to determine a proper set of cognitive tests for different subjects. Most current studies create guidelines of cognitive test selection for a targeted population, but they are not customized for each individual subject. In this manuscript, we develop a machine learning paradigm enabling personalized cognitive assessments prioritization. METHOD: We adapt a newly developed learning-to-rank approach [Formula: see text] to implement our paradigm. This method learns the latent scoring function that pushes the most effective cognitive assessments onto the top of the prioritization list. We also extend [Formula: see text] to better separate the most effective cognitive assessments and the less effective ones. RESULTS: Our empirical study on the ADNI data shows that the proposed paradigm outperforms the state-of-the-art baselines on identifying and prioritizing individual-specific cognitive biomarkers. We conduct experiments in cross validation and level-out validation settings. In the two settings, our paradigm significantly outperforms the best baselines with improvement as much as 22.1% and 19.7%, respectively, on prioritizing cognitive features. CONCLUSIONS: The proposed paradigm achieves superior performance on prioritizing cognitive biomarkers. The cognitive biomarkers prioritized on top have great potentials to facilitate personalized diagnosis, disease subtyping, and ultimately precision medicine in AD. BioMed Central 2020-12-02 /pmc/articles/PMC7709267/ /pubmed/33267852 http://dx.doi.org/10.1186/s12911-020-01339-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Peng, Bo
Yao, Xiaohui
Risacher, Shannon L.
Saykin, Andrew J.
Shen, Li
Ning, Xia
Cognitive biomarker prioritization in Alzheimer’s Disease using brain morphometric data
title Cognitive biomarker prioritization in Alzheimer’s Disease using brain morphometric data
title_full Cognitive biomarker prioritization in Alzheimer’s Disease using brain morphometric data
title_fullStr Cognitive biomarker prioritization in Alzheimer’s Disease using brain morphometric data
title_full_unstemmed Cognitive biomarker prioritization in Alzheimer’s Disease using brain morphometric data
title_short Cognitive biomarker prioritization in Alzheimer’s Disease using brain morphometric data
title_sort cognitive biomarker prioritization in alzheimer’s disease using brain morphometric data
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709267/
https://www.ncbi.nlm.nih.gov/pubmed/33267852
http://dx.doi.org/10.1186/s12911-020-01339-z
work_keys_str_mv AT pengbo cognitivebiomarkerprioritizationinalzheimersdiseaseusingbrainmorphometricdata
AT yaoxiaohui cognitivebiomarkerprioritizationinalzheimersdiseaseusingbrainmorphometricdata
AT risachershannonl cognitivebiomarkerprioritizationinalzheimersdiseaseusingbrainmorphometricdata
AT saykinandrewj cognitivebiomarkerprioritizationinalzheimersdiseaseusingbrainmorphometricdata
AT shenli cognitivebiomarkerprioritizationinalzheimersdiseaseusingbrainmorphometricdata
AT ningxia cognitivebiomarkerprioritizationinalzheimersdiseaseusingbrainmorphometricdata
AT cognitivebiomarkerprioritizationinalzheimersdiseaseusingbrainmorphometricdata